- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03377634
A Mobile Intervention to Reduce Pain and Improve Health (MORPH)
29 december 2020 uppdaterad av: Wake Forest University Health Sciences
A Mobile Intervention to Reduce Pain and Improve Health (MORPH) in Obese Older Adults
Chronic pain contributes to declining health and function in older adults; effects that are intensified by obesity and sedentary (sitting) behavior.
The purpose of this study is to develop and test a novel, patient-centered intervention to reduce pain and improve physical function in older, obese adults.
The study will utilize a combination of telephone based coaching and smartphone tools to deliver this novel intervention to decrease both body weight and sitting behavior.
The long-term goals of this project are to test the efficacy of the intervention and to develop it as a tool for clinicians to provide outside-of-clinic patient-centered support for overweight/obese older adults with chronic pain.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Chronic pain has emerged as an urgent age-related health issue that significantly effects physical functioning and quality of life, with the unfavorable effects worsened by both obesity and sedentary behavior.
The annual cost of pain in the United States is nearly 30% higher than the combined costs of cancer and diabetes.
In 2016, the NIH called for a National Pain Strategy to: 1) expand non-pharmacological treatment options in older adults, who are particularly susceptible to the side effects of opioid and other pain medications; 2) develop accessible treatments that are tailored to individuals; and 3) increase the development of self-management programs for chronic pain.
The purpose of this R-21 is to develop and test the feasibility and acceptability of a novel, patient-centered intervention to reduce chronic pain and improve physical functioning in older adults, leveraging the combination of telecoaching and individually-adaptive mHealth tools to decrease both body mass and sedentary behavior.
A pilot randomized controlled trial will be conducted to provide initial evidence for effect sizes (pain and physical function) associated with the proposed intervention, and to estimate the sample size needed for a full scale randomized controlled trial design that compares the effects of the intervention versus usual care on pain ratings and physical function in overweight/obese older adults with chronic pain.
Studietyp
Interventionell
Inskrivning (Faktisk)
33
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
North Carolina
-
Winston-Salem, North Carolina, Förenta staterna, 27157
- Wake Forest Baptist Medical Center Pain Center
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
65 år till 79 år (Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Own smartphone
- Pain in 2 of 5 areas (i.e., back, neck, shoulders, hips, knees) on most days during the previous 3 months
- No contraindication for participation in exercise with approval for participation by their physician
- Obese (BMI=30-45 kg/m2)
- Weight-stable (i.e., no weight loss or gain > 5% in the past 6 months)
- Low-active (i.e., engaging in less than 2 days/week of structured physical activity for at least 20 minutes).
- Approved for participation by LMC Pain Center Director and Dr. Brooks
- Willingness to provide consent; Agree to all study procedures and assessments; Able to provide own transportation to study visits
- Access to home Wi-Fi and smartphone device
Exclusion Criteria:
- Dependent on cane or walker
- >1 fall (injurious or non-injurious) in past year
- Vision insufficient to read a smartphone screen, unable to read
- Participation in regular resistance training and/or > 20 mins/d of aerobic exercise in past 6 months
- No contraindication to exercise
- Unable to walk without assistive devices
- Cognitive impairment as indicated by a Montreal Cognitive Assessment score < 22
- Uncontrolled hypertension (>160/90 mmHg);
- Current or recent past (within 1 year) severe symptomatic heart disease, uncontrolled angina, stroke, chronic respiratory disease requiring oxygen, neurological or hematological disease; cancer requiring treatment in past yr, except non-melanoma skin cancers
- Regular use of: growth hormones, oral steroids, or prescription osteoporosis medications
- Current participation in other research study targeting pain, physical activity, or weight loss
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Intervention
Participants receive the MORPH intervention.
|
Participants will engage in 12 weekly group coaching sessions discussion behavioral approaches to pain management, weight loss, and daily physical activity.
The first three sessions (i.e., weeks 1 - 3) will occur in-person, and the remaining 9 will take place via telephone.
All intervention participants will receive access to an activity monitor, smart scale, and smartphone app that aims to provide support for daily physical activity and weight loss.
|
Inget ingripande: Control
The wait list control participants receive usual care and are offered intervention materials on completion of the study.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Change in PROMIS Pain Intensity Scale
Tidsram: Baseline to 12 weeks
|
The Pain Intensity Scale tasks participants with rating how much they hurt on a scale of 1 (had no pain) to 5 (very severe).
Final scores are given as T-scores, with higher scores representing worse intensity.
PROMIS scores are a t-score representing relationships with an estimated population average collected on a general US sample of adults as well as clinical samples.
On this t distribution, 50 represents the population average with a standard deviation of 10.
Thus, a score of 55 represents a score that is a half-standard deviation about the US national average, and a 40 represents a score that is 1 standard deviation below the national average.
Scores were computed using the HealthMeasures.org
scoring service as recommended for PROMIS measures.
|
Baseline to 12 weeks
|
Change in PROMIS Pain Interference Scale
Tidsram: Baseline to 12 weeks
|
The Pain Interference Scale captures the impact of pain on valued areas of an individual's life (e.g., how much did pain interfere with your day to day activities) on a scale of 1 (not at all) to 5 (very much).
Final scores are given as T-scores, with higher scores representing worse interference.
PROMIS scores are a t-score representing relationships with an estimated population average collected on a general US sample of adults as well as clinical samples.
On this t distribution, 50 represents the population average with a standard deviation of 10.
Thus, a score of 55 represents a score that is a half-standard deviation about the US national average, and a 40 represents a score that is 1 standard deviation below the national average.
Scores were computed using the HealthMeasures.org
scoring service as recommended for PROMIS measures.
|
Baseline to 12 weeks
|
Change in Short Physical Performance Battery
Tidsram: Baseline to 12 weeks
|
This test of lower-extremity function consists of 4-m walk at usual pace, a timed repeated chair stand, and 3 increasingly difficult standing balance tests.
Each measure is assigned a categorical score ranging from 0 (inability to complete the test) to 4 (best performance) resulting in a final score of 0-12.
Higher scores denotes better outcomes.
|
Baseline to 12 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Change in Weight
Tidsram: Baseline to 12 weeks
|
Weight will be assessed weekly.
|
Baseline to 12 weeks
|
Activity Minutes
Tidsram: Baseline and Week 12
|
Activity Minutes will be assessed using ActivPal activity monitors (PAL Technologies Ltd, Glasgow, UK) worn at the thigh for 7 consecutive days.
We will assess (a) number of daily minutes spent in light-intensity physical activity as reported by the ActivPal (range: 0-1440, more minutes of light activity are favorable); (b) number of daily minutes spent in moderate-intensity physical activity as reported by the ActivPal (range: 0-1440, more minutes of moderate activity are favorable).
|
Baseline and Week 12
|
Sitting Time
Tidsram: Week 12
|
daily minutes of sedentary time as recorded on the ActivPALTM 4 device
|
Week 12
|
Sit to Stand Transitions
Tidsram: Baseline and Week 13
|
Transitions will be assessed using ActivPal activity monitors (PAL Technologies Ltd, Glasgow, UK) worn at the thigh for 7 consecutive days.
We will assess number of daily transitions from sitting to non-sitting behavior, captured via the ActivPal inclinometer (range: 0 - infinity; a higher number of transitions are favorable).
|
Baseline and Week 13
|
Participant Retention
Tidsram: Baseline to 12 weeks
|
The extent to which participants were retained in the study (minimum retention goal of 80%).
The number of participants that complete the study over the number that were enrolled.
|
Baseline to 12 weeks
|
Utilization of Study Application
Tidsram: Baseline to 12 weeks
|
The extent to which participants utilize the study application, as defined by an average weekly use of 7 application accesses per week for the duration of the study period.
|
Baseline to 12 weeks
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Samarbetspartners
Utredare
- Huvudutredare: Amber K Brooks, MD, Wake Forest University Health Sciences
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Allmänna publikationer
- Fanning J, Brooks AK, Ip E, Nicklas BJ, Rejeski WJ, Nesbit B, Ford S. A Mobile Health Behavior Intervention to Reduce Pain and Improve Health in Older Adults With Obesity and Chronic Pain: The MORPH Pilot Trial. Front Digit Health. 2020 Dec;2:598456. doi: 10.3389/fdgth.2020.598456. Epub 2020 Dec 18.
- Fanning J, Brooks AK, Ip E, Nicklas BJ, Rejeski WJ. A Mobile Health Intervention to Reduce Pain and Improve Health (MORPH) in Older Adults With Obesity: Protocol for the MORPH Trial. JMIR Res Protoc. 2018 May 14;7(5):e128. doi: 10.2196/resprot.9712.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
7 augusti 2018
Primärt slutförande (Faktisk)
28 februari 2020
Avslutad studie (Faktisk)
28 februari 2020
Studieregistreringsdatum
Först inskickad
14 december 2017
Först inskickad som uppfyllde QC-kriterierna
14 december 2017
Första postat (Faktisk)
19 december 2017
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
22 januari 2021
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
29 december 2020
Senast verifierad
1 november 2020
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- IRB00046364
- 1R21AG058249-01 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Fetma
-
SanionaAvslutadHypothalamic Injury-induced Obesity (HIO)Danmark
Kliniska prövningar på MORPH
-
Wake Forest UniversityAktiv, inte rekryterandeSmärta | Fetma | Stillasittande beteendeFörenta staterna
-
Infinite Biomedical TechnologiesOkändUnder armbåge amputationFörenta staterna
-
University of Sao Paulo General HospitalAvslutadUtvärdering av Neointimal Healing i oktober av Tapered DES Biomime Morph (TAPER-I-studien) (TAPER-I)ÅderförkalkningBrasilien
-
Meril Life Sciences Pvt. Ltd.Okänd